J0750
J0750 – Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda a · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 28 NDCs crosswalked per 200 mg/300 mg $0.453/unit ASP+6%
📋 J0750 summary
J0750 is a HCPCS Level II J-code used to bill Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescripti..., billed per 200 mg/300 mg. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J0750: Emtricitabine-Tenofovir Disop*, Emtricitabine And Tenofovir Disoproxil Fumarate, Truvada
Code J0750
Billing unit 200 mg/300 mg Payment limit $0.453/unit NDC-Crosswalk 28
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ0750
DescriptorEmtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)
Billing unit200 mg/300 mg
Payment limit / unit$0.453
Est. ASP / unit$0.427 est.
Mapped NDCs28
Data periodQ3 2026
Last updated2026-08-20
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$0.453
Est. ASP / unit
$0.427 est.
Est. after 2% sequester
$0.444
HCPCS dosage
200 mg/300 mg
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionEmtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)
CoverageD — Special coverage instructions apply
Pricing indicator57
Type of service1 — Medical care
BETOS-2O1E
ASC payment group—
Action codeA — Added this year
Effective date2024-01-02
Date added2024-01-02
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J0750 = 200 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J0750 LEAST EXPENSIVE FIRST
28 NDCs map to J0750. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($0.453/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 64380-0719-04 | Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg/1 TABLET | Strides | 30 TABLET in 1 BOTTLE, PLASTIC (64380-719-... | 200 mg/1; 300 mg/1 | 1 | $0.45 | $0.451 | ● Active | PDAC |
| 42543-0719-04 | Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg/1 TABLET | Strides | 30 TABLET in 1 BOTTLE, PLASTIC (42543-719-... | 200 mg/1; 300 mg/1 | 1 | $0.45 | $0.451 | ● Active | PDAC |
| 82009-0109-30 | Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg/1 TABLET, FILM COATED | QUALLENT | 30 TABLET, FILM COATED in 1 BOTTLE (82009-... | 200 mg/1; 300 mg/1 | 1 | $0.45 | $0.505 | ● Active | PDAC |
| 70710-1367-03 | Emtricitabine and tenofovir disoproxil fumarate 200 mg/1; 300 mg/1 TABLET, FILM COATED | Zydus | 30 TABLET, FILM COATED in 1 BOTTLE (70710-... | 200 mg/1; 300 mg/1 | 1 | $0.45 | $0.505 | ● Active | PDAC |
| 69238-2095-03 | Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg/1 TABLET, FILM COATED | Amneal | 30 TABLET, FILM COATED in 1 BOTTLE (69238-... | 200 mg/1; 300 mg/1 | 1 | $0.45 | $0.505 | ● Active | PDAC |
| 65862-0354-30 | Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg/1 TABLET, FILM COATED | Aurobindo | 30 TABLET, FILM COATED in 1 BOTTLE (65862-... | 200 mg/1; 300 mg/1 | 1 | $0.45 | $0.505 | ● Active | PDAC |
| 00093-7704-56 | Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg/1 TABLET, FILM COATED | Teva | 30 TABLET, FILM COATED in 1 BOTTLE (0093-7... | 200 mg/1; 300 mg/1 | 1 | $0.45 | $0.505 | ● Active | PDAC |
| 33342-0106-07 | Emtricitabine and tenofovir disoproxil fumarate 200 mg/1; 300 mg/1 TABLET, FILM COATED | Macleods | 30 TABLET, FILM COATED in 1 BOTTLE (33342-... | 200 mg/1; 300 mg/1 | 1 | $0.45 | $0.505 | ● Active | PDAC |
| 31722-0560-30 | Emtricitabine and tenofovir disoproxil fumarate 200 mg/1; 300 mg/1 TABLET, FILM COATED | Camber | 30 TABLET, FILM COATED in 1 BOTTLE (31722-... | 200 mg/1; 300 mg/1 | 1 | $0.45 | $0.505 | ● Active | PDAC |
| 16714-0534-01 | Emtricitabine and tenofovir disoproxil fumarate 200 mg/1; 300 mg/1 TABLET, FILM COATED | NorthStar | 30 TABLET, FILM COATED in 1 BOTTLE (16714-... | 200 mg/1; 300 mg/1 | 1 | $0.45 | $0.505 | ● Active | PDAC |
| 00904-7172-07 | Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg/1 TABLET, FILM COATED | Major | 30 BLISTER PACK in 1 CARTON (0904-7172-07)... | 200 mg/1; 300 mg/1 | 1 | $0.45 | $0.505 | ● Active | PDAC |
| 42385-0953-30 | Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg/1 TABLET, FILM COATED | Laurus | 30 TABLET, FILM COATED in 1 BOTTLE (42385-... | 200 mg/1; 300 mg/1 | 1 | $0.45 | $0.505 | ● Active | PDAC |
| 76282-0677-30 | EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE 200 mg/1; 300 mg/1 TABLET, FILM COATED | Exelan | 30 TABLET, FILM COATED in 1 BOTTLE, PLASTI... | 200 mg/1; 300 mg/1 | 1 | $0.45 | $0.569 | ● Active | PDAC |
| 59651-0165-30 | Emtricitabine and Tenofovir Disoproxil Fumarate 100 mg/1; 150 mg/1 TABLET, FILM COATED | Aurobindo | 30 TABLET, FILM COATED in 1 BOTTLE (59651-... | 100 mg/1; 150 mg/1 | 0.5 | $0.23 | $10.195 | ● Active | PDAC |
| 70710-1364-03 | Emtricitabine and tenofovir disoproxil fumarate 100 mg/1; 150 mg/1 TABLET, FILM COATED | Zydus | 30 TABLET, FILM COATED in 1 BOTTLE (70710-... | 100 mg/1; 150 mg/1 | 0.5 | $0.23 | $10.195 | ● Active | PDAC |
| 69238-2092-03 | Emtricitabine and Tenofovir Disoproxil Fumarate 100 mg/1; 150 mg/1 TABLET, FILM COATED | Amneal | 30 TABLET, FILM COATED in 1 BOTTLE (69238-... | 100 mg/1; 150 mg/1 | 0.5 | $0.23 | $10.195 | ● Active | PDAC |
| 42291-0980-30 | Emtricitabine and Tenofovir Disoproxil Fumarate 200 mg/1; 300 mg/1 TABLET, FILM COATED | AvKARE | 30 TABLET, FILM COATED in 1 BOTTLE (42291-... | 200 mg/1; 300 mg/1 | 1 | $0.45 | — | ● Active | PDAC |
| 59651-0166-30 | Emtricitabine and Tenofovir Disoproxil Fumarate 133 mg/1; 200 mg/1 TABLET, FILM COATED | Aurobindo | 30 TABLET, FILM COATED in 1 BOTTLE (59651-... | 133 mg/1; 200 mg/1 | 0.666 | $0.30 | — | ● Active | PDAC |
| 59651-0167-30 | Emtricitabine and Tenofovir Disoproxil Fumarate 167 mg/1; 250 mg/1 TABLET, FILM COATED | Aurobindo | 30 TABLET, FILM COATED in 1 BOTTLE (59651-... | 167 mg/1; 250 mg/1 | 0.834 | $0.38 | — | ● Active | PDAC |
| 61958-0704-01 | Truvada emtricitabine and tenofovir disoproxil fumarate 133 mg/1; 200 mg/1 TABLET, FILM COATED | Gilead | 30 TABLET, FILM COATED in 1 BOTTLE, PLASTI... | 133 mg/1; 200 mg/1 | 0.666 | $0.30 | — | ● Active | PDAC |
| 70710-1366-03 | Emtricitabine and tenofovir disoproxil fumarate 167 mg/1; 250 mg/1 TABLET, FILM COATED | Zydus | 30 TABLET, FILM COATED in 1 BOTTLE (70710-... | 167 mg/1; 250 mg/1 | 0.834 | $0.38 | — | ● Active | PDAC |
| 70710-1365-03 | Emtricitabine and tenofovir disoproxil fumarate 133 mg/1; 200 mg/1 TABLET, FILM COATED | Zydus | 30 TABLET, FILM COATED in 1 BOTTLE (70710-... | 133 mg/1; 200 mg/1 | 0.666 | $0.30 | — | ● Active | PDAC |
| 69238-2094-03 | Emtricitabine and Tenofovir Disoproxil Fumarate 167 mg/1; 250 mg/1 TABLET, FILM COATED | Amneal | 30 TABLET, FILM COATED in 1 BOTTLE (69238-... | 167 mg/1; 250 mg/1 | 0.834 | $0.38 | — | ● Active | PDAC |
| 69238-2093-03 | Emtricitabine and Tenofovir Disoproxil Fumarate 133 mg/1; 200 mg/1 TABLET, FILM COATED | Amneal | 30 TABLET, FILM COATED in 1 BOTTLE (69238-... | 133 mg/1; 200 mg/1 | 0.666 | $0.30 | — | ● Active | PDAC |
| 61958-0705-01 | Truvada emtricitabine and tenofovir disoproxil fumarate 167 mg/1; 250 mg/1 TABLET, FILM COATED | Gilead | 30 TABLET, FILM COATED in 1 BOTTLE, PLASTI... | 167 mg/1; 250 mg/1 | 0.834 | $0.38 | — | ● Active | PDAC |
| 61958-0703-01 | Truvada emtricitabine and tenofovir disoproxil fumarate 100 mg/1; 150 mg/1 TABLET, FILM COATED | Gilead | 30 TABLET, FILM COATED in 1 BOTTLE, PLASTI... | 100 mg/1; 150 mg/1 | 0.5 | $0.23 | — | ● Active | PDAC |
| 00378-1930-93 | EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE (FILM-COATED) 200 MG-300 MG | Unknown | — | — | 1 | $0.45 | — | — | PDAC |
| 42291-0439-30 | EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE (FILM-COATED) 200 MG-300 MG | Unknown | — | — | 1 | $0.45 | — | — | PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$118.9K
Claims
1,859
Beneficiaries
1,210
Spend / beneficiary
$98.26
Spend / claim
$63.96
Trend by period
Where J0750 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #556 of 824
#551
COMPLETE AA, PER SQ... Q4303
$124.8K
#552
SODIUM CHLORIDE(J703... J7030
$124.6K
#553
MULTIHANCE A9577
$123.5K
#554
ENGERIX-B ADULT(9074... 90740
$122.1K
#555
AVYCAZ J0714
$119.7K
#556
EMTRICITABINE-TENOFO... J0750
$118.9K
#557
EVOMELA J9246
$116.9K
#558
ZERBAXA J0695
$112.1K
#559
ETOPOPHOS* J9181
$111.1K
#560
TEMODAR J9328
$109.5K
#561
VIBATIV J3095
$109.2K
Total claims — #326 of 824
#321
DILAUDID* J1171
1,926
#322
INVEGA SUSTENNA J2426
1,926
#323
ALBUTEROL SULFATE(J7... J7611
1,926
#324
VINCASAR PFS* J9370
1,920
#325
MITOMYCIN J9280
1,891
#326
EMTRICITABINE-TENOFO... J0750
1,859
#327
ZOLADEX J9202
1,858
#328
DAPTOMYCIN(J0872) J0872
1,843
#329
JEVTANA J9043
1,832
#330
QUZYTTIR J1201
1,770
#331
TOFIDENCE Q5133
1,736
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $118.9K | 1,210 | 1,859 | $98.26 | $63.96 |
| 2025 (Q1-Q4) | $512.8K | 1,865 | 6,191 | $274.95 | $82.83 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$523.6K
Medicare paid
$513.2K
Submitted services
317,166
Denial rate
2.8%
Allowed / service
$1.70
Submitted charges
$16.38M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J0750 is utilized
⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.
📊 What bills under J0750
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
28 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J0750 billing FAQ
What is HCPCS code J0750?
J0750 is a HCPCS Level II J-code used to bill Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv) under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J0750?
One unit of J0750 represents 200 mg/300 mg. Report the number of units equal to the dose administered divided by 200 mg/300 mg.
How many units of J0750 should I bill?
Divide the dose administered by the code's unit size (200 mg/300 mg) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J0750?
The Medicare Part B payment limit is $0.453 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $0.444 per unit. Payment limits are revised quarterly.
Which NDCs bill under J0750?
28 NDCs currently map to J0750 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J0750 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.